Uncategorized
Inotek initiates dosing in phase 3 trial of trabodenoson for glaucoma
Inotek Pharmaceuticals has initiated patient dosing in a pivotal phase 3 clinical trial of trabodenoson for the treatment of glaucoma, the company announced in a press release. The phase 3 MATRx-1 clinical trial of trabodenoson includes 335 patients with primary open-angle glaucoma or ocular hypertension. Patients will receive one of three doses of trabodenoson, and IOP will be measured at four time points at days 14, 28, 42 and 84, the release said.